Amgen Inc. (NASDAQ:AMGN) – Jefferies Group issued their Q3 2017 earnings per share estimates for Amgen in a research note issued on Monday. Jefferies Group analyst M. Yee expects that the medical research company will earn $3.16 per share for the quarter. Jefferies Group has a “Buy” rating and a $200.00 price target on the stock. Jefferies Group also issued estimates for Amgen’s Q4 2017 earnings at $2.99 EPS, FY2017 earnings at $12.57 EPS and FY2018 earnings at $13.01 EPS.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the company earned $2.84 EPS.

COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/11/amgen-inc-expected-to-earn-q3-2017-earnings-of-3-16-per-share-amgn.html.

Other equities analysts have also recently issued research reports about the company. UBS AG reaffirmed a “neutral” rating and issued a $175.00 price target (up previously from $174.00) on shares of Amgen in a report on Tuesday, June 13th. Morgan Stanley upped their price target on Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, June 13th. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price target for the company. in a report on Friday, July 21st. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Finally, Royal Bank Of Canada assumed coverage on Amgen in a report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price target for the company. Ten research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $189.99.

Shares of Amgen (NASDAQ AMGN) opened at 185.79 on Wednesday. The company’s 50-day moving average price is $182.35 and its 200 day moving average price is $170.56. The company has a market cap of $135.57 billion, a P/E ratio of 16.92 and a beta of 1.36. Amgen has a 52 week low of $133.64 and a 52 week high of $191.10.

In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.19% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Camelot Portfolios LLC purchased a new position in Amgen in the first quarter worth approximately $1,429,000. PGGM Investments grew its position in Amgen by 2.3% in the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after acquiring an additional 15,059 shares during the period. Shelton Capital Management boosted its position in shares of Amgen by 82.7% during the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after buying an additional 49,354 shares during the period. Greylin Investment Mangement Inc. boosted its position in shares of Amgen by 466.9% during the second quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock worth $2,416,000 after buying an additional 11,555 shares during the period. Finally, Kelman Lazarov Inc. boosted its position in shares of Amgen by 8.2% during the second quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock worth $272,000 after buying an additional 120 shares during the period. Institutional investors own 78.10% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.